SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Aptevo Reports Fewer Infusion Reactions with Mipletamig in Frontline AML

Aptevo says a refined priming-dose regimen substantially reduced the frequency and severity of infusion reactions, addressing a treatment-tolerability objective identified through FDA discussions.

APVO

Related stories